Effects of glucocorticoids on inflammation and arthritis

Current Opinion in Rheumatology

Volumn 19, Issue 3, 2007, Pages 302-307

  Morand, Eric F ^a,b  

^a MONASH UNIVERSITY   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Glucocorticoid receptor; Glucocorticoids; Mitogen activated protein kinase phosphatase; Osteoporosis; Rheumatoid arthritis

Indexed keywords

ALENDRONIC ACID; ANTICOAGULANT AGENT; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; GOLD; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREDNISOLONE; RU 24858; STEROID; TRIAMCINOLONE; UNCLASSIFIED DRUG; WARFARIN;

AVASCULAR NECROSIS; BODY WEIGHT; BONE DENSITY; BONE EROSION; BONE TURNOVER; CELL DIFFERENTIATION; CLINICAL TRIAL; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG ABSORPTION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG RECEPTOR BINDING; FOLLOW UP; GENE EXPRESSION; GLUCOSE INTOLERANCE; HUMAN; INFLAMMATION; JOINT BIOPSY; LOW DRUG DOSE; OSTEOCLAST; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SEROLOGY; STATISTICAL SIGNIFICANCE; SYNOVITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION; TREATMENT OUTCOME;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; BONE DENSITY; CELL CYCLE PROTEINS; GLUCOCORTICOIDS; HUMANS; IMMEDIATE-EARLY PROTEINS; INFLAMMATION; MAP KINASE SIGNALING SYSTEM; MICE; PHOSPHOPROTEIN PHOSPHATASE; PROTEIN-TYROSINE-PHOSPHATASE; RECEPTORS, GLUCOCORTICOID;

EID: 34247130944     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e32805e87d0     Document Type: Review

References (38)

1. Wassenberg S, Rau R, Steinfeld P, Zeidler H. Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 2005; 52:3371-3380.
2. Svensson B, Boonen A, Albertsson K, et al. Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial. Arthritis Rheum 2005; 52:3360-3370.
3. Harris ED Jr. Prednisolone in early rheumatoid arthritis: an antiinvasive effect. Arthritis Rheum 2005; 52:3324-3325.
4. Kirwan JR. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. N Engl J Med 1995; 333:142-146.
5. Jacobs JW, van Everdingen AA, Verstappen SM, Bijlsma JW. Followup radiographic data on patients with rheumatoid arthritis who participated in a two-year trial of prednisone therapy or placebo. Arthritis Rheum 2006; 54:1422-1428. Long-term followup of a previous prospective study of glucocorticoid use in RA, suggesting long-term protection from adverse radiographic outcomes.
6. Hetland ML, Stengaard-Pedersen K, Junker P, et al. Combination treatment with methotrexate, cyclosporine, and intraarticular betamethasone compared with methotrexate and intraarticular betamethasone in early active rheumatoid arthritis: an investigator-initiated, multicenter, randomized, double-blind, parallel-group, placebo-controlled study. Arthritis Rheum 2006; 54:1401-1409. Although designed to test the effects of cycolosproin, this study demonstrated impressive protective effects of aggressive use of intra-articular glucocorticoid injections in combination with methotrexate in the prevention of erosions.
7. Makrygiannakis D, af Klint E, Catrina SB, et al. Intraarticular corticosteroids decrease synovial RANKL expression in inflammatory arthritis. Arthritis Rheum 2006; 54:1463-1472.
8. Weitoft T, Ronnblom L. Glucocorticoid resorption and influence on the hypothalamic-pituitary-adrenal axis after intra-articular treatment of the knee in resting and mobile patients. Ann Rheum Dis 2006; 65:955-957. A study showing no influence of strict bed-rest on circulating glucocorticoid levels after intra-articular injection.
9. Alex P, Szodoray P, Arthur E, et al. Influence of intraarticular corticosteroid administration on serum cytokines in rheumatoid arthritis. Clin Rheumatol 2006 [Epub ahead of print]. An interesting case report from a study of preinjection and postinjection serum cytokines in RA, showing impressive reductions in circulating cytokines in response to local glucocorticoid injection.
10. Gerlag DM, Boyle DL, Rosengren S, Nash T, Tak PP, Firestein GS. Real-time quantitative PCR to detect changes in synovial gene expression in rheumatoid arthritis after corticosteroid treatment. Ann Rheum Dis 2006 [Epub ahead of print]. A larger study of synovial cytokine expression after intra-articular glucocorticoid therapy with surprisingly selective effects on cytokine expression as measured.
11. Tseng CE, Buyon JP, Kim M, et al. The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: findings of a prospective, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006; 54:3623-3632. A prospective study of glucocorticoid therapy in SLE based on serological, not clinical, indicators to start or increase therapy, which suggested a reduction in clinical flares and overall glucocorticoid exposure.
12. Lems WF, Lodder MC, Lips P, et al. Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial. Osteoporos Int 2006; 17:716-723. A prospective study confirming the protective effect of alendronate on glucocorticoid-induced losses of BMD in RA.
13. da Silva JAP, Jacobs JWG, Kirwan JR, et al. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheum Dis 2006; 65:285-293. A most interesting study comparing 'standard' glucocorticoid toxicities with data from prospective trials of low-dose glucocorticoid therapy in RA, which concluded that many well known toxicities are not seen in this clinical context.
14. Nagasawa K, Tada Y, Koarada S, et al. Prevention of steroid-induced osteonecrosis of femoral head in systemic lupus erythematosus by anticoagulant. Lupus 2006; 15:354-357.
15. Duma D, Jewell CM, Cidlowski JA. Multiple glucocorticoid receptor isoforms and mechanisms of posttranslational modification. J Steroid Biochem Mol Biol 2006; 102:11-21. An excellent review of glucocorticoid receptor biology and the importance of glucocorticoid receptor isoforms.
16. Lu NZ, Cidlowski JA. Translational regulatory mechanisms generate N-terminal glucocorticoid receptor isoforms with unique transcriptional target genes. Mol Cell 2005; 18:331-342.
17. Goleva E, Li L-b, Eves PT, et al. Increased glucocorticoid receptor beta alters steroid response in glucocorticoid-insensitive asthma. Am J Respir Crit Care Med 2006; 173:607-616.
18. Kozaci DL, Chernajovsky Y, Chikanza IC. The differential expression of corticosteroid receptor isoforms in corticosteroid-resistant and -sensitive patients with rheumatoid arthritis. Rheumatology (Oxford) 2006 [Epub ahead of print]. Application of glucocorticoid receptor isoform knowledge to RA with investigation of glucocorticoid receptor isoform expression in RA patient peripheral blood leukocytes.
19. Li L-b, Leung DYM, Hall CF, Goleva E. Divergent expression and function of glucocorticoid receptor b in human monocytes and T cells. J Leukoc Biol 2006; 79:818-827.
20. Chivers JE, Gong W, King EM, et al. Analysis of the dissociated steroid, RU24858, does not exclude a role for inducible genes in the antiinflammatory actions of glucocorticoids. Mol Pharmacol 2006; 70:2084-2095.
21. Adcock IM, Caramori G, Ito K. New insights into the molecular mechanisms of corticosteroids actions. Curr Drug Targets 2006; 7:649-660. an excellent review of the state of the art of glucocorticoid mechanisms of action, although directed at the clinical setting of chronic obstructive pulmonary disease.
22. Hardy RS, Filer A, Cooper MS, et al. Differential expression, function and response to inflammatory stimuli of 11beta-hydroxysteroid dehydrogenase type 1 in human fibroblasts: a mechanism for tissue-specific regulation of inflammation. Arthritis Res Ther 2006; 8:R108. Expression and function of glucocorticoid receptor isoforms in RA cells.
23. Morand EF, Leech M, Bernhagen J. MIF: a new cytokine link between rheumatoid arthritis and atherosclerosis. Nat Rev Drug Discov 2006; 5:399-410. A review of the evidence for the glucocorticoid-induced proinflammatory cytokine MIF as a therapeutic target in both RA and atherosclerosis, suggesting a link between these pathologies based on disease-induced and glucocrticoid-induced MIF overexpression.
24. Hermanowski-Vosatka A, Balkovec JM, Cheng K, et al. 11beta-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice. J Exp Med 2005; 202:517-527.
25. Roger T, Chanson AL, Knaup-Reymond M, Calandra T. Macrophage migration inhibitory factor promotes innate immune responses by suppressing glucocorticoid-induced expression of mitogen-activated protein kinase phosphatase-1. Eur J Immunol 2005; 35:3405-3413.
26. Aeberli D, Yang YH, Mansell A, et al. Macrophage migration inhibitory factor modulates glucocorticoid sensitivity in macrophages via effects on MAP kinase phosphatase-1 and p38 MAP kinase. FEBS Lett 2006; 580:974-981. Demonstration of the regulation of glucocorticoid sensitivity in vitro by MIF.
27. Aeberli D, Leech M, Morand EF. Macrophage migration inhibitory factor and glucocorticoid sensitivity. Rheumatology (Oxford) 2006; 45:937-943.
28. Radstake TR, Sweep FC, Welsing P, et al. Correlation of rheumatoid arthritis severity with the genetic functional variants and circulating levels of macrophage migration inhibitory factor. Arthritis Rheum 2005; 52:3020-3029.
29. Berdeli A, Ozyurek AR, Ulger Z, et al. Association of macrophage migration inhibitory factor gene -173 G/C polymorphism with prognosis in Turkish children with juvenile rheumatoid arthritis. Rheumatol Int 2006; 26:726-731.
30. Toh M-L, Aeberli D, Lacey D, et al. Regulation of IL-1 and TNF receptor expression and function by endogenous MIF. J Immunol 2006; 177:4818-4825.
31. Zhao Q, Wang X, Nelin LD, et al. MAP kinase phosphatase 1 controls innate immune responses and suppresses endotoxic shock. J Exp Med 2006; 203:131-140. Demonstration of the important constituitive inhibitory effect of MKP-1 on pathways of innate immune activation and cytokine expression.
32. Salojin KV, Owusu IB, Millerchip KA, et al. Essential role of MAPK phosphatase-1 in the negative control of innate immune responses. J Immunol 2006; 176:1899-1907. Demonstration of the important constituitive inhibitory effect of MKP-1 on pathways of innate immune activation, cytokine expression, and murine collageninduced arthritis.
33. Toh M-L, Yang Y, Leech M, Morand EF. Expression of MAP kinase phosphatase-1, a negative regulator of MAP kinases, in rheumatoid arthritis: upregulation by IL-1 and glucocorticoids. Arthritis Rheum 2004; 50:3118-3128.
34. Yang Y, Morand EF, Getting SJ, et al. Modulation of inflammation and response to dexamethasone by annexin-1 in antigen-induced arthritis. Arthritis Rheum 2004; 50:976-984.
35. Morand EF, Hall P, Hutchinson P, Yang YH. Regulation of annexin I in rheumatoid synovial cells by glucocorticoids and interleukin-1. Mediat Inflamm 2006; 2006:73835.
36. Ito K, Yamamura S, Essilfie-Quaye S, et al. Histone deacetylase 2-mediated deacetylation of the glucocorticoid receptor enables NF-κB suppression. J Exp Med 2006; 203:7-13. Demonstration of the importance of HDAC2 in regulation of glucocorticoid receptor acetylation, and therefore glucocorticoid sensitivity.
37. Kim H-J, Zhao H, Kitaura H, et al. Glucocorticoids suppress bone formation via the osteoclast. J Clin Invest 2006; 116:2152-2160. Demonstration of novel actions of glucocorticoids on bone, dependent on osteoclast-mediated osteoblast inhibition rather than increased osteoclast-mediated resorption.
38. Swanson C, Lorentzon M, Conaway HH, Lerner UH. Glucocorticoid regulation of osteoclast differentiation and expression of receptor activator of nuclear factor-κB (NF-κB) ligand, osteoprotegerin, and receptor activator of NF-κB in mouse calvarial bones. Endocrinology 2006; 147:3613-3622. Demonstration of a conflicting result, wherein glucocorticoids activated bone resorption in whole bone cultures.